Comparison of selected molecular abnormalities or co‐expression with MET amplification in signaling pathways as well as PD‐L1 expression
| Other genetic abnormalities . | MET non‐amp (n = 205, 88.0%), n (%) . | MET amp (n = 28, 12.0%), n (%) . | Overall molecular abnormalities, n (%) . |
|---|---|---|---|
| TP53 | 83 (40.0) | 16 (57.0) | 99 (42.0) |
| HER2 amplification | 35 (17.0) | 5 (18.0)a | 40 (17.0) |
| CDKN2A | 16 (8.0) | 3 (11.0) | 19 (8.0) |
| PIK3CA | 14 (7.0) | 3 (11.0) | 17 (7.0) |
| KRAS/NRAS | 13 (6.0) | 2 (7.0) | 15 (6.0) |
| EGFR amplification | 10 (5.0) | 2 (7.0) | 12 (5.0) |
| FGFR1, FGFR2 | 5 (2.0) | 1 (4.0) | 6 (3.0) |
| ALK | 1 (0.5) | 0 (0) | 1 (0.5) |
| PD‐L1 testing: CPSb | 19/34 (56.0) | 4/6 (67.0) | 23/40 (58.0) |
| Other genetic abnormalities . | MET non‐amp (n = 205, 88.0%), n (%) . | MET amp (n = 28, 12.0%), n (%) . | Overall molecular abnormalities, n (%) . |
|---|---|---|---|
| TP53 | 83 (40.0) | 16 (57.0) | 99 (42.0) |
| HER2 amplification | 35 (17.0) | 5 (18.0)a | 40 (17.0) |
| CDKN2A | 16 (8.0) | 3 (11.0) | 19 (8.0) |
| PIK3CA | 14 (7.0) | 3 (11.0) | 17 (7.0) |
| KRAS/NRAS | 13 (6.0) | 2 (7.0) | 15 (6.0) |
| EGFR amplification | 10 (5.0) | 2 (7.0) | 12 (5.0) |
| FGFR1, FGFR2 | 5 (2.0) | 1 (4.0) | 6 (3.0) |
| ALK | 1 (0.5) | 0 (0) | 1 (0.5) |
| PD‐L1 testing: CPSb | 19/34 (56.0) | 4/6 (67.0) | 23/40 (58.0) |
aFour were MET+/HER2+ on initial biopsy, and one was MET+ on biopsy after trastuzumab.
bA total 40 patients were tested for PD‐L1; CPS ≥1 was considered positive.
Abbreviations: CPS, combined positive score; MET amp, MET‐amplified; MET non‐amp, non–MET‐amplified.
Comparison of selected molecular abnormalities or co‐expression with MET amplification in signaling pathways as well as PD‐L1 expression
| Other genetic abnormalities . | MET non‐amp (n = 205, 88.0%), n (%) . | MET amp (n = 28, 12.0%), n (%) . | Overall molecular abnormalities, n (%) . |
|---|---|---|---|
| TP53 | 83 (40.0) | 16 (57.0) | 99 (42.0) |
| HER2 amplification | 35 (17.0) | 5 (18.0)a | 40 (17.0) |
| CDKN2A | 16 (8.0) | 3 (11.0) | 19 (8.0) |
| PIK3CA | 14 (7.0) | 3 (11.0) | 17 (7.0) |
| KRAS/NRAS | 13 (6.0) | 2 (7.0) | 15 (6.0) |
| EGFR amplification | 10 (5.0) | 2 (7.0) | 12 (5.0) |
| FGFR1, FGFR2 | 5 (2.0) | 1 (4.0) | 6 (3.0) |
| ALK | 1 (0.5) | 0 (0) | 1 (0.5) |
| PD‐L1 testing: CPSb | 19/34 (56.0) | 4/6 (67.0) | 23/40 (58.0) |
| Other genetic abnormalities . | MET non‐amp (n = 205, 88.0%), n (%) . | MET amp (n = 28, 12.0%), n (%) . | Overall molecular abnormalities, n (%) . |
|---|---|---|---|
| TP53 | 83 (40.0) | 16 (57.0) | 99 (42.0) |
| HER2 amplification | 35 (17.0) | 5 (18.0)a | 40 (17.0) |
| CDKN2A | 16 (8.0) | 3 (11.0) | 19 (8.0) |
| PIK3CA | 14 (7.0) | 3 (11.0) | 17 (7.0) |
| KRAS/NRAS | 13 (6.0) | 2 (7.0) | 15 (6.0) |
| EGFR amplification | 10 (5.0) | 2 (7.0) | 12 (5.0) |
| FGFR1, FGFR2 | 5 (2.0) | 1 (4.0) | 6 (3.0) |
| ALK | 1 (0.5) | 0 (0) | 1 (0.5) |
| PD‐L1 testing: CPSb | 19/34 (56.0) | 4/6 (67.0) | 23/40 (58.0) |
aFour were MET+/HER2+ on initial biopsy, and one was MET+ on biopsy after trastuzumab.
bA total 40 patients were tested for PD‐L1; CPS ≥1 was considered positive.
Abbreviations: CPS, combined positive score; MET amp, MET‐amplified; MET non‐amp, non–MET‐amplified.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
